To further assess the expression of GCNT2 in clinical melanoma samples, we developed a dual immunohistochemical (IHC) staining approach using GCNT2 and melanocyte lineage marker, microphthalmia-associated transcription factor (MITF) antibodies to help distinguish GCNT2 in melanocytes/melanoma cells from other cell types. Here, MITF is linked to melanoma.